Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,194.87 +14.13 (+0.27%) Dow
38,928.80 +76.53 (+0.20%) Nasdaq
16,380.87 +31.62 (+0.19%) Bitcoin USD
63,789.00 +532.65 (+0.84%) CMC Crypto 200
1,323.66 -41.47 (-3.03%)
LLY Jan 2025 180.000 put
| Previous close | 1.2300 |
| Open | 1.2300 |
| Bid | 0.0000 |
| Ask | 3.2000 |
| Strike | 180.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.6000 - 1.2300 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
Insider MonkeyKevin O’Leary’s Stock Portfolio: 10 Stock Picks for 2024
In this article, we discuss the 10 companies to consider in the portfolio of Kevin O’Leary for 2024. If you want to skip our overview of O’Leary’s investment philosophy and learn about some more companies in his stock portfolio, go directly to Kevin O’Leary’s Stock Portfolio: 5 Stock Picks for 2024. Kevin O’Leary, affectionately known […]
- Reuters
UPDATE 2-US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10
Eli Lilly said on Tuesday a panel of independent U.S. FDA advisers will discuss its experimental Alzheimer's disease drug, donanemab, on June 10. Donanemab has faced two separate regulatory delays in the United States, while a similar therapy by Eisai and partner Biogen, called Leqembi, received the U.S. Food and Drug Administration's approval last year. Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its approval.
Simply Wall St.Eli Lilly First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Eli Lilly ( NYSE:LLY ) First Quarter 2024 Results Key Financial Results Revenue: US$8.77b (up 26% from 1Q 2023). Net...
